This open-label, unblinded study included 257 patients in 53 US clinics with a diagnosis of CFS and FM. All subjects were given D-ribose (as Corvalen™ from Bioenergy), a naturally occurring pentose carbohydrate, 5 g t.i.d. for three weeks.
In the 203 patients who completed the trial, D-ribose treatment led to both statistically and clinically highly important average improvements in all categories:
- 61.3-percent increase in energy
- 37-percent increase in overall well being
- 29.3-percnet improvement in sleep
- 30-percent improvement in mental clarity
- 15.6-percent decrease in pain
Improvement began in the first week of treatment, and continued to increase at the end of the three weeks of treatment. The D-ribose was well tolerated.
These findings confirmed results of an earlier pilot study published in the Journal of Alternative and Complementary Medicine, involving 36 patients from a single medical centre, who took D-ribose for an average of 25 days. Approximately 66 percent of patients experienced significant improvement while on D-ribose, with an average increase in energy of 45 percent and an average improvement in overall well-being of 30 percent.
“Our hypothesis all along has been that giving D-ribose to people with chronic fatigue syndrome and fibromyalgia will jump-start their mitochondrial energy furnaces,” said Dr Teitelbaum. “We’re pleased that the larger multicentre trial corroborated our earlier study, showing the same benefits for fibromyalgia and chronic fatigue syndrome patients from multiple locations.”